SymBio Pharmaceuticals Ltd - ESG Rating & Company Profile powered by AI
The Disclosure score covers 17 UN Sustainable Development Goals including: 'Quality Education', 'Reduced Inequalities' and 'Life on Land'. If you are employed by SymBio Pharmaceuticals Ltd and you would like to licence your ESG rating, please contact us. The page contains a zero-cost Environmental, Social and Governance analysis for SymBio Pharmaceuticals Ltd.
SymBio Pharmaceuticals Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.4; made up of an environmental score of 2.0, social score of 8.0 and governance score of 3.2.
4.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 868 | Trevena Inc | 4.5 | High |
| 868 | Urogen Pharma Ltd | 4.5 | High |
| 910 | SymBio Pharmaceuticals Ltd | 4.4 | High |
| 910 | CanBas Co Ltd | 4.4 | High |
| 910 | CNS Pharmaceuticals Inc | 4.4 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does SymBio Pharmaceuticals Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd report the average age of the workforce?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd offer flexible work?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd conduct supply chain audits?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose water use targets?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid SymBio Pharmaceuticals Ltd have a product recall in the last two years?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas SymBio Pharmaceuticals Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose parental leave metrics?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs SymBio Pharmaceuticals Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose its waste policy?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd report according to TCFD requirements?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose energy use targets?
Sign up for free to unlockDoes SymBio Pharmaceuticals Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes SymBio Pharmaceuticals Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for SymBio Pharmaceuticals Ltd
These potential risks are based on the size, segment and geographies of the company.
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.